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Abstract
Objective
Adipose Tissue Stromal Cells (ASCs) have important clinical applications in the regener-
ative medicine, cell replacement and gene therapies. Subcutaneous Adipose Tissue
(SAT) is the most common source of these cells. The adult human thymus degenerates
into adipose tissue (TAT). However, it has never been studied before as a source of stem
cells.
Material and Methods
We performed a comparative characterization of TAT-ASCs and SAT-ASCs from myocar-
dial ischemic subjects (n = 32) according to the age of the subjects.
Results
TAT-ASCs and SAT-ASCs showed similar features regarding their adherence, morphology
and in their capacity to form CFU-F. Moreover, they have the capacity to differentiate into
osteocyte and adipocyte lineages; and they present a surface marker profile corresponding
with stem cells derived from AT; CD73+CD90+CD105+CD14-CD19-CD45-HLA-DR. Inter-
estingly, and in opposition to SAT-ASCs, TAT-ASCs have CD14+CD34+CD133+CD45-
cells. Moreover, TAT-ASCs from elderly subjects showed higher adipogenic and osteo-
genic capacities compared to middle aged subjects, indicating that, rather than impairing;
aging seems to increase adipogenic and osteogenic capacities of TAT-ASCs.
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Conclusions
This study describes the human TAT as a source of mesenchymal stem cells, which may
have an enormous potential for regenerative medicine.
Introduction
Mesenchymal stem cells are a heterogeneous population of stem cells capable of self-renewing
and differentiating into osteoblasts, chondrocytes, adipocytes, myocytes, cardiomyocytes,
fibroblasts, myofibroblasts, epithelial and neural cells [1]. These unique properties make them
of great interest for tissue engineering and regenerative medicine [2]. Although they are found
mainly in the bone marrow, they can also be found in the Adipose Tissue (AT), peripheral
blood, umbilical cord, liver, and foetal tissues, among others. Once isolated, they have been cul-
tured which has allowed studying their phenotypic and functional features [3,4].
Several studies have found that AT is a feasible abundant source of mesenchymal stem cells
for regenerative medicine [5] and that these cells can be isolated in a reliable and reproducible
manner [6] in comparison to mesenchymal stem cells from bone marrow [7].
Given that mesenchymal stem cells have considerable therapeutic potential, and have gener-
ated markedly increasing interest in a wide variety of biomedical disciplines, The Mesenchymal
and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes
minimal criteria to define human mesenchymal stem cells [8]: 1) These cells must be plastic-
adherent when maintained in standard culture conditions; 2) They must express CD105, CD73
and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 and
HLA-DR surface molecules; 3) They must differentiate to osteoblasts, adipocytes and chondro-
blasts in vitro.
The thymus is largest and most active during the neonatal and pre-adolescent periods. By
the early teens, the thymus begins to atrophy and thymic stroma is mostly replaced by mature
AT [9]. Previous studies have highlighted the adult thymus as a potential source of ASCs [10–
12]. Our group has been investigating the potential use of thymus fat as a source for cellular
therapy for heart neovascularization after cardiopulmonary bypass interventions (CPB) on
myocardial ischemic elderly subjects. These subjects cannot benefit from coronary revasculari-
zation treatment after surgery or angioplasty. Part of the thymus fat is discarded in aortic can-
nulation procedures of the ascending aorta in cardiovascular surgery in patients with a need of
a CPB. Therefore, it is an available source of TAT. We have previously described that adult thy-
mus fat from myocardial ischemic subjects presents a similar cellular profile as that observed in
other white adipose tissues such as SAT. This cellular variety seems to be responsible for the
observed differences in the expression of a variety of genes that are known to be relevant in the
regulation of the neo genesis of adipocytes and of other cell types such as endothelial [13].
These data suggested that it would be relevant to analyze whether TAT is a source of mesen-
chymal stem cells and to compare the characteristics of these cells with those from SAT.
Materials and Methods
Patients and adipose tissue collection
The study was performed conform the declaration of Helsinki and recruited myocardial ische-
mic patients (n = 32) who received a coronary-artery bypass graft with a CPB in the Carlos
Haya Hospital. The mean number of grafts used was 3.1 per patient. The subjects operated on
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and recruited in this study were individuals with stable situations and without severe ischemic
injury. Therefore, these subjects were without infarct or with a previous infarct at least 6
months before surgery. For the stromal vascular fraction (SVF) cell proliferation assay, Fibro-
blast Colony Forming Units assay (CFU-F assay) and flow cytometry study, the number of
patients with similar clinical characteristics was 6 (all of them with an age 70 years). The dif-
ferentiation assays and mRNA expression analysis were performed on two groups of patients:
the middle-aged group, aged from 45, and the elderly group of patients with myocardial ische-
mia. The number of patients recruited for the study of adipogenic and osteogenic differentia-
tion was 26 (n = 8 middle aged, and n = 18 elderly). The local ethical committee of the Carlos
Haya Hospital approved this study, and the Spanish Society of Thoracic and Cardiovascular
Surgery (SECTCV) obtained signed informed consent from all participating patients. The rele-
vant clinical and metabolic characteristics of these subjects are shown in Table 1. Both SAT
and TAT were obtained at the beginning of the procedure and before heart arrest. The site of
SAT harvest was from the chest incision. Fresh tissues were immediately processed for mesen-
chymal cell extraction and flow cytometry or characterization.
Isolation and expansion of cells from the SVF of TAT and SAT
Isolation and expansion of cells from SVF was performed as previously described [14] with
modifications. Briefly, both SAT and TAT were obtained and transported in Hank's balanced
salt solution supplemented with penicillin and streptomycin. AT biopsies were washed with
PBS, dissected into smaller pieces under sterile conditions, and subjected to enzymatic diges-
tion with a solution containing 0.150% collagenase type I and 1.0% bovine serum albumin
(BSA) for 70 min at 37°C. The cell suspension was centrifuged at 500 x g for 10 min. Floating
adipocytes were discarded and the pellet containing the SVF was filtered through a 100-μm
mesh, and centrifuged at 400×g for 5 min. The cell pellets were re-suspended in erythrocyte
lysis buffer for 10 min at room temperature and centrifuged at 400 x g for 5 min. Cell pellets
were then suspended in expansion medium DMEM/F12 supplemented with 10% fetal bovine
serum, 100 μg/ml streptomycin, 100 U/ml penicillin, 1 μg/ml amphotericin B and 2 mM L-glu-
tamine. Cells were them plated in tissue culture flasks and incubated at 37°C in a humid atmo-
sphere with 5% of CO2 for approximately 8 days until 90% confluence was reached. The cells
were always used between passages one/three.
Table 1. Clinical variables of Myocardial Ischemic Subjects (n = 32).
Parameters Middle- aged (n = 18) Elderly (n = 18) P
Age (years) 45–65  70
Triglycerides (mg/dL) 149.00 ± 20.67 129.0 ±20.72 NS
Cholesterol (mg/dL) 180.50 ±12.92 183.92±8.48 NS
HDL-c (mg/dL) 50.63 ± 8.86 49.08±3.34 NS
LDL-c (mg/dL9 101.58 ± 10.86 109.03±6.28 NS
Creatinine (mg/dL) 1.085 ± 0.14 1.36±0.36 NS
Hb1Ac(%) 13.33 ±0.67 12.31±0.42 NS
Hematocrit (%) 40.53 ±1.87 37.97±1.35 NS
BMI (kg/m2) 30.59 ±1.19 28.08±0.88 NS
Values are means ± SEM. Comparisons between both groups were carried out using the Mann-Whitney U Test. HDL-C: Cholesterol HDL, LDL-c:
Cholesterol LDL, BMI: Body Mass Index, NS: No significant.
doi:10.1371/journal.pone.0144401.t001
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SVF Cell proliferation assay
Cells from the SVF from each donor (n = 6) were seeded in triplicate in 12 well plates at 5000
cells per cm2 in complete expansion medium. Cells were dissociated by trypsin and counted
every 48 hours for 23 days using the trypan blue exclusion method.
Population doubling assay
5000 ASCs from SAT and TAT of each donor (n = 6) were seeded in triplicate on 12 well plates.
The cells were cultured until reaching confluence, dissociated by trypsin, and counted using
the trypan blue exclusion method. The population doublings (PDs) were calculated using the
following equation: PDs = 240/Log2 (N2/N1), where N1 and N2 represent the average cell
number at 5th and 15th day, respectively.
Colony Forming Unit-Fibroblastic (CFU-F) assay
Cells from the SVF of each donor (n = 6) were seeded in triplicate in 6 well plates at 50 cells per
cm2. The cells were cultured for 14 days under standard conditions (37°C in a 5% CO2 moist
atmosphere). At day 14, medium was removed and resultant colonies were washed twice with
PBS, fixed with absolute methanol and stained with 0.5% crystal violet for 20 minutes at room
temperature. The plates were washed with water, and colonies containing more than 50 cells
were counted.
Immunophenotypic characterization by flow cytometry
Cells from the SVF at passage 3 were immunophenotyped by flow cytometry using cell surface
markers CD14, CD34, CD45, CD73, HLA-DR (BD Pharmigen, EEUU), CD29, CD31, CD44,
CD49D, CD19, CD90, CD105, CD106, CD133, CD144, CD146, (eBioscience), CD140A,
CD140B, CD166 (RD Systems, EEUU). The clone, fluorochrome and amount of each antibody
are provided in S1 Table. Briefly, 106cells/ml were resuspended in blocking buffer solution con-
taining PBS supplemented with 3.0% BSA, and incubated on ice for 10 minutes. Then, they
were gated according to their granularity (SS) and size (FS). 1x105 cells were stained using the
antibodies (0.25 μg x 106 cells in 100 μl PBS) against the above surface markers or the isotype-
matched control antibody. Samples were analyzed on a FACScan CyAnTM High-speed ADP
Analyzer (Beckman Coulter, CA. EEUU). Data acquisition and analysis were performed using
SUMMIT 3 software (Beckman Coulter). Unstained cells were used to establish flow cytometer
settings. Debris and cells/particles with auto-fluorescence were removed by using a threshold
on the forward scatter. The original (RAW) set of data is shown in S1 Fig.
In vitro adipogenic and osteogenic differentiation assay
Cells from SVF of TAT and SAT were harvested at passage 3 and seeded in 6 well plates at
10,000 cells per cm2 in expansion medium until reaching 90% confluence. The expansion
medium was changed every 2–3 days, and replaced with adipogenic or osteogenic medium at
day 14.
The adipogenic induction medium was DMEM/F12 supplemented with 10% FBS, strepto-
mycin 100 μg/ml, penicillin 100 U/ml, L-glutamine 2 mM, insulin 10 μM, isobutilmetilxantine
0.5 mM, dexamethasone 1.0 μM, pioglitazone 10 μM, rosiglitazone 0.5 μM, biotin 33 μM, and
pathenonate 17 μM. After 72h of adipogenic induction, the medium was replaced by the above
medium without Biotin and Pathenonate. Adipogenesis was confirmed after 14 days by oil Red
O staining to visualize the characteristic cytoplasmic lipid droplets.
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The osteogenic differentiation was performed with DMEM/F12 containing FBS 10%, strep-
tomycin 100 μg/mL, penicillin 100 U/mL, L-glutamine 2 mM, dexamethasone 1.0 μM, ascorbic
acid 200 μM, and β-glycerolphosphate 20 mM. The osteogenic potential was evaluated by
assessment of calcium deposition by Alizarin Red S staining.
Quantitative reverse transcriptase polymerase chain reaction (RT-PCR)
analysis
Total RNA was isolated using the RNA-Stat 60 Reagent (Ams Biotechnology, UK). The ampli-
fications were performed using a MicroAmp optical 96-well reaction plate (PE Applied Biosys-
tems) on an ABI 7500 real-time PCR system (Applied Biosystems). RT qPCR reactions were
carried out for all genes using specific TaqMan gene expression assays. During PCR, the Ct val-
ues for each amplified product were determined using a threshold value of 0.1. The specific sig-
nals were normalized by constitutively expressed cyclophilin (4326316E) signals according to
the formula 2−ΔCt.
TaqMan1 gene expression assay probes:
SREBP1 Hs00967385_g1
FABP-4 Hs01086177_m1
LPL Hs00173425_m1
FASN Hs00188012_m1
ADRP Hs00765634_m1
CEBPα Hs00269972_s1
ALPL Hs01029144_m1
Statistical analysis
The results are given as mean and standard errors mean (±SEM). All clinical parameters are
summarized by descriptive statistics (Table 1). Relationships between TAT and SAT, and
between the elderly and middle-aged groups were performed using Mann-Whitney U test.
Relationships between control wells and differentiation wells were performed using a signed
rank test (Wilcoxon). Correlation analysis was performed using a Spearman’s correlation coef-
ficient test (r). In all cases, the rejection level for a null hypothesis was α = 0.05 for two tails.
The statistical analysis was carried out with the SPSS software program (Version 15.0 for Win-
dows; SPSS, Chicago, IL).
Results
Clinical and biological variables of both patient groups
Table 1 shows that there were no significant differences in clinical and biological variables
between the two groups.
Comparative analysis of the ability to adhere to plastic and form CFU-F
of TAT-ASCs and SAT-ASCs
SAT-ASCs and TAT-ASCs showed a similar ability to adhere to plastic culture plates, and dis-
played elongated and flattened fibroblastic morphology, a morphology compatible with clono-
genic cell colonies, the characteristics of human Mesenchymal Stem Cells (Fig 1A). A CFU-F
assay was performed in order to quantify the differences between TAT-ASCs and SAT-ASCs.
As shown in Fig 1B, no significant differences were observed between TAT-ASCs (7.45±1.29)
and SAT-SCs (8.55±1.42).
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Comparative analysis of the growth kinetics of TAT-ASCs and
SAT-ASCs
We next analyzed the growth rate of cultured TAT-ASCs and SAT-ASCs by counting the cell
number at the indicated days (Fig 2A). The two cell types did not show significant differences
in the average doubling time (103.13±8.24h for TAT-ASCs and 88.86 ±6.89h for SAT-ASCs)
(Fig 2B), however, SAT-ASCs had a significantly higher proliferation rate than TAT-ASCs.
Immunophenotype characterization of TAT-ASCs and SAT-ASCs by
flow cytometry
We next conducted a comparative flow cytometric analysis of the identified TAT-ASCs popu-
lation and SAT-ASCs in order to characterize the CD marker profiles of these cells. As shown
in Fig 3, both cell types were CD105+, CD166+, CD73+, CD90+, CD29+, CD44+, CD106+,
CD49D+, CD140b+, and negative for the hematopoietic cell surface markers CD45, HLA-DR,
CD144, CD140a, CD31 and CD14; and the percentages of positive cells were similar for both
cell types.
Fig 1. Comparison of colony forming units–fibroblast (CFU-Fs) between human thymus and subcutaneous adipose tissue-derived stromal cells
(TAT-ASCs and SAT-ASCs). TAT and SAT derived- stromal cells (TAT-ASCs and SAT-ASCs) were extracted from the tissues of myocardial ischemic
subjects (n = 6) and were seeded in triplicate in 6 well plates at 50 cells/cm2. The cells were cultured for 14 days under standard conditions (37°C in a 5%
CO2moist atmosphere). At day 14 cells were stained with crystal violet and colonies containing more than 50 cells were counted. (A) Microscopic image of
adhered cells to plastic dishes. (B) Microscopic image of representative colony of each cell type (TAT-ASCs and SAT-ASCS). The results are representative
of four independent experiments. Scale bars = 100 μm. *P <0.05. The graph bar represents mean ± SEM. The comparison between the two ASC types were
carried out with Mann-Whitney U-Test. Image magnification is 4X.
doi:10.1371/journal.pone.0144401.g001
Fig 2. Proliferative characteristics of human thymus and subcutaneous adipose tissue derived stromal cells (TAT-ASCs and SAT-ASCs). TAT and
SAT derived-stromal cells (TAT-ASCs and SAT-ASCs) were extracted from the tissues of myocardial ischemic subjects (n = 6) and were seeded in triplicate
in 12 well plates at 5000 cells per cm2 in complete expansion medium. Cells were dissociated by trypsin and counted every 48 hours for 23 days using the
Trypan Blue exclusion method. (A) Curve growth kinetics of TAT-ASCs and SAT-ASCs. Values presented in the graph represent the mean ± SE of the
values obtained from each donor and which were done in triplicate. (B) The population doublings (PDs) were calculated using the following equation:
PDs = 240/Log2 (N2/N1), where N2 and N1 represent the average cell number at 15th and 5th day, respectively. The comparison between the two ASC
types were carried out with Mann-Whitney U-Test.*p<0.05; **p<0.01.
doi:10.1371/journal.pone.0144401.g002
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Fig 3. Phenotypic characterization of human thymus and subcutaneous adipose tissues derived stromal cells (TAT-ASCs and SAT-ASCs) at 3rd
passage. Representative histograms of six analyzed patient samples and percentage of positive cells for each of the markers analyzed of TAT-ASCs and
SAT-ASCs. 1x105 cells from passage 3 were labeled with the described markers or the isotype-matched control antibody. Samples were analyzed on a
FACScan CyAnTMHigh-speed ADP Analyzer (Beckman Coulter, CA. EEUU). Values as mean ± SEM were obtained from each donor (n = 6). The
comparison between the two ASC types were carried out with Mann-Whitney U-Test.*p<0.05.
doi:10.1371/journal.pone.0144401.g003
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Three surface markers were distinctive between the two cell types. CD14 expression was
higher in TAT-ASCs (23.81±11.76%) than in SAT-ASCs (6.00±1.12%.), and CD133 and CD34
were significantly higher in TAT-ASCs (27.06±6.82; 35.5±7.44) than in SAT-ASCs (3.29±0.50;
3.38±1.32).
Differentiation capacity of TAT-ASCs and SAT-ASCs
Adipogenic and osteogenic differentiation are usually defined, respectively, by the appearance
of cells containing intracellular lipid droplets under Oil Red-O staining, and enhanced alkaline
phosphatase expression and mineralization under alizarin red staining. As shown in Fig 4A,
both types of ASCs were able to differentiate into adipocytes after 14 days of culture in adipo-
genic medium as evidenced the presence of lipids droplets. In addition, increased mRNA levels
of adipogenic markers were also found (Fig 4B). Enhanced alkaline phosphatase (ALPL)
mRNA expression levels and positive staining by alizarin red indicated that both cell types
were able to differentiate into osteoclasts in the present of osteogenic culture medium (Fig 5).
Age-related changes in the adipogenic and osteogenic capacity of
TAT-ASCs and SAT-ASCs
In order to analyze whether the age could influence the differentiation capacity of TAT-ASCs
and SAT-ASCs, we next analyzed the expression levels of adipogenic and osteogenic markers
expression levels according to the age of the subjects. As shown in Fig 6, adipogenic differenti-
ated TAT-ASCs and SAT-ASCs from elderly subjects showed higher levels of the adipogenic
markers ADRP and CEBPαmRNAs than those from middle-aged subjects. TAT-ASCs from
elderly subjects showed higher levels of the osteogenic marker ALPL than those from middle-
aged subjects, while SAT-ASCs from elderly subjects showed lower levels of this marker com-
pared with cells from the middle-aged group (Fig 6).
Discussion
Adipose Tissue–Derived Stromal Cells (AT-ASCs) are one of the most promising sources of
stem cells for tissue engineering applications [14,15]. Several groups have shown that stem cells
from the SVF of SAT display multi-lineage developmental plasticity [8,16]. It is therefore
important to identify and characterize new sources of these cells within ATs in order to select
the best suited for such applications. The aim of this study was to investigate the easily accessi-
ble thymus fat from adult subjects with myocardial ischemia as a source of AT-ASCs in com-
parison with SAT-ASCs.
The results described here show that the human adult thymus fat is a good candidate source
of ASCs. Several lines of evidence verify this claim: 1) TAT-ASCs present fibroblastic morphol-
ogy and are able to adhere to plastic; 2) They can be cultured and expanded over 20 cycles with-
out showing signs of senescence [3,17]; 3) They have the ability to form CFU-F; 4) They have
the capacity to differentiate into osteocytes and adipocytes lineages; and 5) They present a sur-
face marker profile corresponding with stem cells derived from AT; CD73+CD90+CD105+-
CD14-CD19-CD45-HLA-DR- [4,18,19]. As shown, these parameters were similar between
TAT-ASCs and SAT-ASCs. All together these data indicate that TAT-ASCs meet the criteria
established by the International Society for Cellular Therapy (ISCT) [8]. In our analysis we
found that SAT-ASCs have the tendency to have lower average doubling time compared to
those from TAT-ASCs, however, the differences are not significant. These subtle differences
seem to be enough to make a cumulative effect that is shown as a significant increase of the
total cell number since day 7 of proliferation.
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On the other hand, TAT-ASCs showed high capacity to differentiate into the most relevant
cells lineages, osteocytes and adipocytes.
In opposition to SAT-ASCs and other AT-ASCs [3,20], the immunophenotype analysis
showed the presence of CD34+ CD133+ and CD45- cells which differs from those detected in
Fig 4. Adipogenic differentiation of human thymus and subcutaneous adipose tissues derived stromal cells (TAT-ASCs and SAT-ASCs).
Representative photomicrographs of cells obtained from thymus fat (TAT-ASCs) (A) and from subcutaneous adipose tissue (SAT-ASCs) (B) (n = 26) grown
in adipogenic medium for 14 days. Adipogenic differentiation of AASCs was confirmed by detecting the accumulation of the lipophilic marker, Oil Red O, over
time in lipid droplets of adipose cells. (C) Adipogenic process confirmation was carried out by mRNA expression analysis of the adipogenic markers FABP4,
LPL, FASN, ADRP, CEBPα and SREBP1α. mRNAs were normalized to cyclophilin expression levels. Each sample from each subject was analyzed
separately and in triplicate. Data represent the mean ± SEM of the values obtained from all samples. The relation between control and adipogenic
differentiation was analyzed by range test with Wilcoxon sign. *p<0.05. Image magnification is 20X.
doi:10.1371/journal.pone.0144401.g004
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SAT-ASCs, this suggesting the potential existence of a subpopulation CD34+ CD133+ CD45-,
which has been described as endothelial progenitor cells that contribute to vasculogenic activity
and vessels formation [21,22]. It is important to highlight that CD34 is a known marker of
hematopoietic stem cells, vascular endothelial cells and their precursors [23–25]. Here CD45-
phenotype of TAT-ASCs precludes contamination by haematopoietic cells [26]. In agreement
with our data, Russo et al. have recently described that ASCs isolated from thymus remnant fat
had a longer average doubling time and a significantly higher proportion of CD34+ cells, as
compared with cells isolated from subcutaneous fat or the omentum [11].
CD14+ cells have been previously described as cells with the capacity to differentiate into
functional endothelial cells and so-called “endothelial-like cells” or ‘early endothelial progeni-
tor cells" (EPC) [27–29]. Here we show that in stark contrast to other known AT-ASCs [32],
TAT-ASCs contain CD14+ cells. Interestingly, and also in opposition to what happens specifi-
cally in SAT-ASCs, TAT-ASCs contain both CD14+ and CD34+ cells. Altogether the discovery
of the CD34+CD133+CD14+ subpopulation from TAT-ASCs have great interest for the vascu-
lar regenerative medicine scientific community, as it has been shown that interaction of CD14+
cells with CD34+ cells potentiates the capacity of CD14+ cells to differentiate into endothelial-
like cells [30–33]. Here we show that both ASCs are CD146- cells. The expression of this cellu-
lar marker is well known to decrease with successive culture passages [34].
One important feature of stem cells is the differentiation capacity. It has been previously
described that SAT-ASCs have higher differentiation capacity than other AT-ASCs [35–37]. In
this sense, we found that the differentiation capacity of TAT-ASCs is similar to that of SAT-
ASCs. This suggests that TAT-ASCs could represent another suitable source of ASCs.
It has been described that aging declines the proliferation rate, the doubling time as well as
the differentiation capacities of AT-ASCs [38,39]. The differentiation capacity is widely
accepted to be associated with a decreased expression of key regulator of adipogenic events
[40–42]. On the other hand, we found that aging increased the differentiation capacity of
SAT-ASCs and TAT-ASCs from patients with myocardial ischemia rather than decrease it, as
shown by the increased levels of the adipogenic markers, ADRP and CEBPα, in cells from
elderly subjects (Fig 6).
The osteogenic differentiation capacity of AT-ASCs has been described to get progressively
impaired with aging [38,43,44]. Here we show that TAT-ASCs and SAT-ASCs have similar
osteogenic differentiation capacity. However, this capacity was higher in TAT-ASCs than in
SAT-ASCs with age as evidenced by the higher expression of the master oteogenic regulator,
ALPL, in TAT-ASCs from elderly subjects than from middle age subjects. Our results highlight
that it is of interest to evaluate the potential use of TAT-ASCs in osteogenic regeneration and
therapy in elderly subjects.
It is well known that osteoblasts and adipocytes share a common mesenchymal ancestor
[45]. Recent in vitro evidence suggests that agonists of osteogenic differentiation act as antago-
nists of adipogenic diferentiation and vice versa [46]. Our results highlight that adipogenic dif-
ferentiation capacity was increased in both aging TAT and SAT, while osteogenic
Fig 5. Osteogenic differentiation of human thymus and subcutaneous adipose tissues derived
stromal cells (TAT-ASC and SAT-ASC).Representative photomicrographs of cells obtained from thymus
fat (TAT-ASCs) (A) and from subcutaneous adipose tissue (SAT-ASCs) (B) (n = 26) grown in osteogenic
medium for 14 days. Osteogenic differentiation of ASCs was confirmed by detecting calcium deposition by
Alizarin Red S staining. (C) Osteogenic process confirmation was carried out by mRNA expression analysis
of the osteogenic marker ALPL. mRNAs were normalized to cyclophilin expression levels. Each sample from
each subject was analyzed separately and in triplicate. Data represent the mean ± SEM of the values
obtained from all samples. The relationship between control and osteogenic differentiation was analyzed by
range test with Wilcoxon sign. *p<0.05. Image magnification is 20X.
doi:10.1371/journal.pone.0144401.g005
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differentiation capacity was decreased in SAT but significantly increased in TAT. This raises
the questions of whether the inverse relationship between adipogenic and osteogenic capacities,
is applicable to TAT from myocardial ischemic subjects. Further research is required to illumi-
nate this important matter.
In summary, in spite of the fact that ASCs are an appealing source of cells for therapeutic
intervention, the environment from which these cells are isolated may impact their usefulness.
To date, the age, the adipose tissue depot site, and some pathologies such as metabolic syn-
drome have been shown to affect negatively stemness and angiogenic capacity of ASCs [47–
49], suggesting that caution should be exercised when considering the source of ASCs for cellu-
lar therapies since their therapeutic potential may be impaired [50]. Another source of stem
cells that is commonly investigated is bone marrow, however, it is widely accepted that aging
impairs their proliferation and differentiation potentials. In fact, it has been shown that aging
decreases proliferation capacity, senescence and doubling time of bone marrow derived stem
cells compared to adipose tissue derived stem cells [51,52]. These data evidence that in elderly
subjects the AT is a more suitable source of stem cells than the bone marrow.
Altogether, our data suggest that TAT from elderly cardiomyopathy ischemic subjects may
be a suitable source of ASCs for the cell-based neovascularization therapy in general, and for
subjects with myocardial ischemia, in particular.
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